Pharmaceutical composition based on 3-(4-methylimidazole-1-yl)imidazo[1,2-b][1,2,4,5]tetrazine as anti-tumor agent

FIELD: pharmaceutics.

SUBSTANCE: invention relates to pharmaceutical industry and includes pharmaceutical composition, which is solution of pharmaceutically acceptable substance 3-(4-methylimidazole-1-yl)imidazo[1,2-b][1,2,4,5]tetrazine of formula (I) and D-mannitol in water. Composition is used for therapy of malignant tumors in human or animal.

EFFECT: technical result is obtaining stable, long-term stored solution of Substance 1.

1 cl

 



 

Same patents:

FIELD: chemistry.

SUBSTANCE: invention relates to a method of lyophilisation of a composition, which contains purified antithrombin III (AT III) and a crystallised substance, selected from alanine, mannitol, glycine or NaCl. The claimed method includes freezing the composition at a temperature from -52C to -60C for 6-15 hours, annealing the composition at -30C for 1 hour, re-freezing the composition at a temperature from -52C to -60C for 2-15 hours at keeping the product temperature between -48C and -52.7C for 4-10 before lyophilisation and drying the composition with obtaining a lyophilised cake. The invention also relates to a pharmaceutical set, which contains the said lyophilised cake and a liquid reagent.

EFFECT: invention provides obtaining the lyophilised composition, containing AT III, which preserves its activity and stability.

14 cl, 24 dwg, 5 tbl, 2 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: group of inventions relates to medicine. Described is a composition for the transdermal introduction of medications (M) into a human and animal organism, including cases of urgent drug treatment and prevention of acute pathological conditions. The composition consists of a solution of one or several M in a mixture of at least two solvents: dialkylamide of lower carboxylic acid and (or) alkylpyrrolidone and monoterpenes and (or) monoterpenoids. The total volume concentration of N,N-dialkylamides of lower carboxylic acids or N-alkylpyrrolidones constitutes from 1% to 99% of the mixture volume.

EFFECT: composition makes it possible to realise urgent drug treatment and prevention of acute pathological conditions of a human and animal organism by a simple in implementation, safe and cheap method.

12 cl, 6 dwg, 4 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to compounds or their pharmaceutically acceptable salts which can be applicable for biologically active substances delivery.

EFFECT: invention refers to pharmaceutical formulations containing the above compounds, and to a method for administering the biologically active substances.

17 cl, 10 tbl, 19 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: present invention refers to medicine, namely to pharmacology and describes a histidine-free pharmaceutical composition containing high-purity factor VIII; arginine and saccharose, a surfactant for the prevention or at least the inhibition of a surface adsorption of factor VIII; 0.5 to 10 mM calcium chloride for the specific stabilisation of factor VIII, and sodium citrate or maleic acid as a pH buffer.

EFFECT: invention provides the protective function for preserve high-yield factor VIII over the whole cycle of pharmaceutical processing, long storage and end recovery and administration into the patient.

18 cl, 16 tbl, 8 ex

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely to dermatooncology, and can be used in treatment of actinic keratosis. For this purpose foci of disease are identified with further carrying out their US-examination and derma analysis. In case if hypoechogenic zone, occupying from 5% to 30% of entire derma thickness, is present in derma, applications with liquid nitrogen with textile tip are performed. In case if hypoechogenic zone, occupying from 30% to 70% of entire derma thickness, is detected, applications with liquid nitrogen with copper tip or photodynamic therapy with application of photosensitiser are performed. In case if hypoechogenic zone, occupying from 70% to entire derma thickness, is detected, photodynamic therapy with application of photosensitiser is carried out.

EFFECT: method makes it possible to select tactics of treating said pathology in the most accurate way basing not only on clinical manifestations of disease, but also due to taking into account proliferative abilities of cells, which excludes necessity of carrying out tissue biopsy.

3 dwg, 4 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely rheumatology, and is applicable for preventing and treating rheumatoid arthritis in a patient. That is ensured by the oral administration of a therapeutically effective amount of calcitonin in the free form or in the form of a salt or a delivery agent specified in a group specified in N-(5-chlorosalicyloyl)-8-aminocaprylic acid (5-CNAC), N-(10-[2- hydroxybenzoyl]amino)decanoic acid (SNAD), N-(8-[2-hydroxybenzoyl]amino)caprylic acid (SNAC) and their pharmaceutically acceptable salts.

EFFECT: oral introduction promotes improved absorption, more acceptable pharmacokinetic and pharmacodynamic profile and a smaller degree of calcitonin variability, as compared with the other methods of delivery that provides reduced chondrolysis.

8 cl, 2 dwg, 2 tbl, 4 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: group of inventions relates to pharmacy and medicine. Pharmaceutical composition includes mixture of: (a) active macromolecular substance; (b) aromatic alcohol, absoption amplifier, selected from propylgallate, butylated hydroxytotuol (BHT), butylated hydroxyanisole (BHA) and their analogues and derivatives, or their mixtures; and (c) biguanide or its pharmaceutically acceptable salt, capable of increasing solubility of aromatic alcohol, absorption amplifier, in water medium, where aromatic alcohol, absorption amplifier, is present in amount (by weight) greater or equal to amount of active substance. Application in pharmaceutical composition of aromatic alcohol, selected from propylgallate, BHT, BHA and their analogues and derivatives, together with biguanide or its pharmaceutically acceptable salt, capable of increasing solubility of aromatic alcohol in water medium, as amplifier of macromolecule absorption through intestine wall. Method of increasing absorption of active macromolecular substance and method of patient treatment include introduction of claimed composition to patient. Application of active macromolecular substance, selected from insulin, C-peptide, GLP-1 or their mixture; aromatic alcohol, absorption amplifier, selected from propylgallate, butylated hydroxytotuol (BHT), butylated hydroxyanisole (BHA) and their analogues and derivatives, or their mixtures; and biguanide or its pharmaceutically acceptable salt, capable of increasing solubility of aromatic alcohol, absorption amplifier, in water medium, in manufacturing medications for treatment of diabetes, osteoporosis, obesity, cancer, osteoarthritis.

EFFECT: group of inventions ensures facilitation of passage of peptides, proteins and other macromolecular substances through intestinal wall for improvements of their bioavailability.

27 cl, 3 tbl, 11 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to method of obtaining composition, including lyophilised one, containing epoprostenol, which includes obtaining solution of epoprostenol or its salt and arginine and bringing solution pH to more than 12 by addition of potassium hydroxide or sodium hydroxide. Invention also relates to pharmaceutical composition and stable solution for treatment of cardio-vascular diseases, which contain epoprostenol or its salt and arginin and have pH higher than 12. Also described is method of treating patient with cardio-vascular disease, which includes introduction of effective amount of said composition.

EFFECT: invention ensures obtaining hemocompatible, stable to microorganisms and stable epoprostenol compositions.

46 cl, 30 tbl, 5 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to medicine, namely to pharmaceutical compositions containing a peptide and propylene glycol, to methods of preparing such compositions, and also concerns methods of reducing contamination of injection devices by a peptide composition and reducing sediment formation in the production equipment during manufacturing of the peptide composition. The agonist GLP-1 is used as said peptide in the composition.

EFFECT: reduced contamination of the injection devices during injection.

23 cl, 6 ex, 7 dwg

FIELD: medicine.

SUBSTANCE: offered invention refers to medicine, namely to surgery, and can be used for prevention of inconsistency of anastomoses of hollow organs in gastrointestinal tract surgery. That is ensured by the oral introduction of 5-oxymethyluracil pills of the weight 1.5 g and diameter 7-7.5 mm on the 2nd postoperative day in the following proportions: 5-oxymethyluracil - 0.5 g, 5 % spirit-acetone acetylphthalylcellulose - 3 layers, 10 % hexane solution of low-molecular polyethylene - 1-3 layers, biological adhesive Sulphacrylate - 1-3 layers.

EFFECT: introduction of 5-oxymethyluracil in said dosage form provides stimulation of repair regeneration ensured by selective maximum concentration of the preparation in gastrointestinal segments where the anastomosis has been created, and reduced ischemic disorders.

1 ex, 1 dwg

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to the chemical-pharmaceutical industry and represents a substance-delivering carrier for the substance delivery to a bone marrow cell producing an extracellular matrix containing retinoid as a delivering agent, wherein the substance is a therapeutic agent, which inhibits the beginning, progression and/or recurrence of myelofibrosis.

EFFECT: invention provides the effective inhibition of the beginning, progression and recurrence of myelofibrosis.

10 cl, 14 dwg, 8 ex

FIELD: medicine.

SUBSTANCE: declared is a pharmaceutical composition for oral administration, containing methisoprinol, methyl n-hydroxybenzoate, propyl-n-hydroxybenzoate, saccharose or maltose, glycerol, citrus flavouring and purified water.

EFFECT: composition has a pleasant flavour and storage-stable.

2 ex, 1 tbl, 5 dwg

FIELD: medicine.

SUBSTANCE: invention represents a biologically active composition in the form of an orally disintegrating tablet characterised by the fact that it contains dehydroepiandrosterone (DHEA) as an active component, or its combination with theanine, and inert filling agents: mannitol, sorbitol, maltitol, crospovidone, copovidone, a lubricant, an intensive sweetening agent and a flavouring agent in certain mixture ratio.

EFFECT: composition is stable and has high bioavailability.

4 cl, 3 ex

FIELD: chemistry.

SUBSTANCE: claimed invention relates to biodegradable water-insoluble polyethyleneglycol-based hydrogels. The claimed invention also deals with conjugates of such biodegradable hydrogels with affinity ligands or chelating groups or ion-exchange groups, bound with carriers of prodrugs, in which a biodegradable hydrogel in accordance with the claimed invention is the carrier, and their pharmaceutical compositions, as well as to their application as a drug. Described is a biodegradable water-insoluble poly(ethyleneglycol)-based hydrogel, containing fragments of the main chain, connected by hydrolytically degradable bonds, with fragments of the main chain being characterised by the molecular weight in the range from 1 kDa to 20 kDa and having the structure C*-(A-Hyp)x, where C* represents a branching core, A represents a polymer poly(ethyleneglycol)-based chain, Hyp represents a super-branched dendrite fragment, x represents an integer number from 3 to 15; and where the superbranched dendrite fragment additionally contains reactionable functional groups and connecting functional groups, with the fragments of the main chain being connected together by means of cross-linking fragments, and each cross-linking fragment has at least two hydrolytically degradable bonds at the end. A conjugate and a bound with the carrier prodrug, containing the said biodegradable hydrogel, and the application of the prodrug in a medication are also described. Also described are: a method of obtaining the said hydrogel, which includes a stage (a) reacting of a main chain reagent, and the hydrogel, obtained by the claimed method, in the form of a coating mesh, a stent or a microparticle, obtained by crashing by mechanical methods, such as mixing, breaking, cutting pressing or milling, and sieving in case of necessity.

EFFECT: disclosed are the methods of obtaining the prodrug, the method of obtaining the prodrug, injected through the needle, and the prodrug, obtained by the claimed method.

38 cl, 41 ex, 15 dwg

FIELD: medicine.

SUBSTANCE: invention aims at treating drug-induced dry eye syndrome (DI-DES). Treating DI-DES implies taking the past medical history, measuring tear production and eye xerosis values reduced and increased respectively in relation to the norm. Unpreserved ocular hypotensive medications are prescribed in the patient. Unpreserved artificial tears are also applied. The lachrymal fluid is analysed by a multicytokine technique. If the analysis shows increased concentrations of proinflammatory cytokines - interleukin-6, interleukin-8, interleukin-12, Th-1 - interleukin-2, interferon-gamma, and Th-2 - interleukin-4, by min 30% in relation to the patient's age norm, a chronic immune ocular inflammation is detected. That requires transpalpebral Blepharogel-1 phonophoresis and 1% hydrocortisone ointment phonophoresis on the sub-mastoidal region from both sides; the therapeutic course is 8-10 daily procedures.

EFFECT: optimal conditions for diagnosing and reasoned differentiated therapy of DI-DES that enables prescribing the pathogenetically reasoned therapy in due time and increasing the efficacy of the therapeutic exposure.

1 tbl, 2 ex

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely to immunology, and describes set for preservation of native erythrocytes, applied for detection of antibodies to antigens of erythrocytes, consists of two solutions: water solution for short-term stay of erythrocytes, which contains 9.0-11.0 g/l of glucose, 0.2-0.3 g/l of sodium citrate, 0.01-0.02 g/l of citric acid and 0.95-1.05 g/l of bull serum albumin, and water solution for storing erythrocytes, which includes 0.2-0.4 g/l of adenine, 25.0-35.0 g/l of glucose, 6.0-8.0 g/l of mannitol, 0.2-0.3 g/l of sodium citrate, 0.05 -0.07 g/l of citric acid and 0.95-1.05 g/l of bull serum albumin.

EFFECT: invention ensures preserving ability of antigens of membrane of preserved native erythrocytes to bind with respective clinically significant antibodies for term not less than 2 months.

3 cl, 1 tbl

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to medicine. Described is medical form for transmucousal per oral introduction of, at least, one active substance of antispasmodic and/or analgesic action, which contains said active substance in form of base and/or in form of salt, water-alcohol solution, with alcoholic content, at least, 35 of alcohol by weight, with said active substance being present in water-alcohol solution in condition of stable and complete dissolution. Invention also relates to method of said medical form preparation and its application for treating spastic attacks.

EFFECT: medical form makes it possible to realise instantaneous transmucousal per oral introduction.

10 cl

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to medicine, more specifically to an implanted device comprising a biologically compatible, biologically degradable polymer mixed with TMC278 (rilpivirine) and with one or more release-enhancing agents specified in a group consisting of poloxamers, polysorbates and a combination of dimethylsulphoxide (DMSO) and poly(vinylpyrrolidone) (PVP).

EFFECT: device provides the extended release of the active ingredient for long periods of time.

17 cl, 3 dwg, 5 tbl, 7 ex

FIELD: medicine.

SUBSTANCE: composition has an action of the central nervous system; it is presented in the form of a solution, contains glycine, glycerol, a preserving agent and water. The invention also concerns a therapeutic agent and a biologically active addition based on the above composition.

EFFECT: group of inventions provides high bioavailability as the composition is presented in the liquid and ease of dosing.

12 cl, 2 tbl, 3 ex

FIELD: medicine.

SUBSTANCE: invention provides a stable composition for treating damages associated with herpes-virus infections in a form specified in creams and gels containing low-level trichloroacetic acid. The amount of trichloroacetic acid makes less than 6% (wt / wt) of the cream or gel.

EFFECT: extending the range of products for treating the damages associated with herpes-virus infections.

25 cl, 3 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to a chemical compound of formula wherein R=benzyl and to an antituberculous therapeutic agent representing a composition of imidazo[1,2-b][1,2,4,5]tetrazine derivative of formula I, wherein R=benzyl, isopropyl or phenyl and the known antituberculous preparation pyrazinamide with the ingredients in mole ratio 1:1.

EFFECT: there are prepared new antituberculous therapeutic agents.

2 cl, 2 tbl, 6 ex

Up!